Ruxolitinib Phosphate is a potent Janus kinase (JAK) inhibitor utilized in the treatment of intermediate or high-risk myelofibrosis, a chronic myeloproliferative neoplasm. As a critical pharmaceutical… Read more
Ruxolitinib Phosphate is a potent Janus kinase (JAK) inhibitor utilized in the treatment of intermediate or high-risk myelofibrosis, a chronic myeloproliferative neoplasm. As a critical pharmaceutical compound, the accurate analysis of its chemical profile is essential for pharmaceutical development and quality control. This category provides a comprehensive selection of Ruxolitinib Phosphate reference standards, including the active pharmaceutical ingredient, its related enantiomers, and stable isotope labelled compounds such as deuterated analogues. These materials are indispensable for laboratories conducting rigorous analytical testing, including impurity profiling, method validation, and pharmacokinetic research. By utilizing these high-quality standards, analytical chemists can reliably identify and quantify trace impurities or monitor metabolic pathways in biological matrices, ensuring compliance with regulatory requirements and supporting the overall safety and efficacy of the therapeutic product.